Clal Biotechnology Industries Stock Current Ratio
| CBI Stock | 37.80 1.40 3.85% |
Clal Biotechnology Industries fundamentals help investors to digest information that contributes to Clal Biotechnology's financial success or failures. It also enables traders to predict the movement of Clal Stock. The fundamental analysis module provides a way to measure Clal Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Clal Biotechnology stock.
Clal |
Clal Biotechnology Industries Company Current Ratio Analysis
Clal Biotechnology's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Clal Biotechnology Current Ratio | 3.67 X |
Most of Clal Biotechnology's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Clal Biotechnology Industries is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, Clal Biotechnology Industries has a Current Ratio of 3.67 times. This is 26.12% higher than that of the Biotechnology sector and 47.57% lower than that of the Health Care industry. The current ratio for all Israel stocks is 69.91% lower than that of the firm.
Clal Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Clal Biotechnology's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Clal Biotechnology could also be used in its relative valuation, which is a method of valuing Clal Biotechnology by comparing valuation metrics of similar companies.Clal Biotechnology is rated third in current ratio category among its peers.
Clal Fundamentals
| Return On Equity | -0.45 | |||
| Return On Asset | -0.12 | |||
| Profit Margin | (1.14) % | |||
| Operating Margin | (0.86) % | |||
| Current Valuation | 89.12 M | |||
| Shares Outstanding | 156.85 M | |||
| Shares Owned By Insiders | 64.58 % | |||
| Price To Earning | (218.28) X | |||
| Price To Book | 0.68 X | |||
| Price To Sales | 2.79 X | |||
| Revenue | 76.96 M | |||
| Gross Profit | 10.72 M | |||
| EBITDA | (98.18 M) | |||
| Net Income | (89.58 M) | |||
| Cash And Equivalents | 94.71 M | |||
| Cash Per Share | 0.59 X | |||
| Total Debt | 52.28 M | |||
| Debt To Equity | 6.30 % | |||
| Current Ratio | 3.67 X | |||
| Book Value Per Share | 0.84 X | |||
| Cash Flow From Operations | (41.33 M) | |||
| Earnings Per Share | (0.57) X | |||
| Target Price | 30.0 | |||
| Number Of Employees | 21 | |||
| Beta | 0.9 | |||
| Market Capitalization | 122.65 M | |||
| Total Asset | 444.92 M | |||
| Retained Earnings | (823 M) | |||
| Working Capital | 193 M | |||
| Current Asset | 254 M | |||
| Current Liabilities | 61 M | |||
| Z Score | -0.2 | |||
| Annual Yield | 0.18 % | |||
| Net Asset | 444.92 M |
About Clal Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clal Biotechnology Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clal Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clal Biotechnology Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Clal Stock
Clal Biotechnology financial ratios help investors to determine whether Clal Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Clal with respect to the benefits of owning Clal Biotechnology security.